Technical Analysis for HGEN - Humanigen Inc.

Grade Last Price % Change Price Change
grade A 5.43 -4.74% -0.2700
HGEN closed down 4.74 percent on Thursday, July 9, 2020, on 68 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical HGEN trend table...

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -4.74%
Pocket Pivot Bullish Swing Setup -4.74%
Parabolic Rise Strength -4.74%
Wide Bands Range Expansion -4.74%
Above Upper BB Strength -4.74%
Older signals for HGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Medicine Medical Specialties Clinical Medicine Biopharmaceutical Antibodies Cancers Immune System Immunotherapy Cancer Immunotherapy Monoclonal Antibodies Chimeric Antigen Receptor T Cell Glioblastoma Multiforme

Is HGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.19
52 Week Low 0.3
Average Volume 434,033
200-Day Moving Average 1.1535
50-Day Moving Average 2.5368
20-Day Moving Average 4.2135
10-Day Moving Average 4.5320
Average True Range 0.8466
ADX 31.11
+DI 33.6228
-DI 17.9418
Chandelier Exit (Long, 3 ATRs ) 3.6502
Chandelier Exit (Short, 3 ATRs ) 4.7898
Upper Bollinger Band 5.8334
Lower Bollinger Band 2.5936
Percent B (%b) 0.88
BandWidth 76.8909
MACD Line 0.7064
MACD Signal Line 0.6184
MACD Histogram 0.088
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.6990
Resistance 3 (R3) 6.7047 6.2873 6.4875
Resistance 2 (R2) 6.2873 5.9642 6.2845 6.4169
Resistance 1 (R1) 5.8587 5.7645 5.6500 5.8530 6.3465
Pivot Point 5.4413 5.4413 5.3370 5.4385 5.4413
Support 1 (S1) 5.0127 5.1182 4.8040 5.0070 4.5135
Support 2 (S2) 4.5953 4.9185 4.5925 4.4431
Support 3 (S3) 4.1667 4.5953 4.3725
Support 4 (S4) 4.1610